News - Page 33 of 36 - MaRS Innovation
OtoSim Inc. to Appear on BNN’s The Pitch
OtoSim Inc., a MaRS Innovation spin-off company, is taping an appearance on Business News Network’s The Pitch on May 22, 2012.
Louis Hui, OtoSim’s business development manager, will have 90 seconds to pitch OtoSim™ — an integrated educational system that dynamically and interactively teaches how to accurately diagnose ear diseases — to The Pitch’s panel of financiers and experts. (more…)
Read more
ScarX Therapeutics Featured on Front Page of the Globe and Mail
MaRS Innovation's ScarX Therapeutics, a strategic partnership with The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek), was featured on the front page of the Globe and Mail on May 7, 2010.
Read the article on Globe and Mail.com (note that depending on when you're accessing this page, the Globe's content may be subject to a pay wall).
(more…)
Read more
MaRS Innovation Forms Strategic Drug-Development Partnership with NovoTek Therapeutics Inc. in China
MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.
This project was covered in The Globe and Mail on May 7, 2012.
(more…)
Read more
ApneaDX Inc: A Medical Device to Accurately Diagnose Sleep Apnea at Home
MaRS Innovation and the University Health Network's Toronto Rehabilitation Institute have collaborated to bring a new technology to market that accurately diagnoses sleep apnea at the patient's home.
Sleep apnea is a medical disorder that is gaining increasing recognition as a major health issue. It is estimated that six to eight per cent of the world's population suffer from the disease, but 85 per cent are undiagnosed.
Undiagnosed sleep apnea is estimated to cause $3.4 billion in additional medical costs in the US.
...
Read more
Xagenic Raises $10 million in Series A Financing
TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million.
The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund. (more…)
Read more
Top 100 Hall of Fame welcomes Mary Jo Haddad
Mary Jo Haddad, President and CEO, has been inducted into the Canada’s Most Powerful Women: Top 100 Hall of Fame.
Haddad received the Canada’s Most Powerful Women: Top 100 Award, presented by the Women’s Executive Network (WXN), in 2007, 2008 and 2009.
Connie Sugiyama, Past Chair of the SickKids Board of Trustees, was also selected as one of Canada’s Most Powerful Women in the “Trailblazers & Trendsetters” category.
Canada’s Most Powerful Women: Top 100 Awards has become one of Canada’s most recognizable honours and ...
Read more
Encycle investigators receive CQDM investment
CQDM invests $1.5 million in two collaborative projects within the Québec/Ontario Life Sciences Corridor
Toronto, December 6, 2011 — The Québec Consortium for Drug Discovery (CQDM) is pleased to announce $1.5 million in funding for two joint Québec/Ontario research projects in biomedical research.
The news was released today at the conference, Connecting Life Sciences Across the Ontario-Québec Corridor, which was held in Toronto. (more…)
Read more
Prestigious Award: MaRS Innovation Board Member Ilse Treurnicht named one of Canada’s Most Powerful Women
MaRS Discovery District and MaRS Innovation congratulate CEO Dr. Ilse Treurnicht for being recognized as one of Canada’s top 100 female achievers in the private, public and not-for-profit sectors.
For a second time, Dr. Treurnicht has been honoured with the prestigious Canada’s Most Powerful Women: Top 100™. Award in the Trailblazers & Trendsetters category. Her first Top 100™ win was announced in 2009. (more…)
Read more
DLVR Therapeutics Inc. adds MaRS Innovation to investor base
TORONTO, Ontario, Canada – October 24, 2011 – DLVR Therapeutics Inc. (“DLVR”) - a privately-held biotechnology company currently focused on developing oncology therapeutics based on its proprietary high density lipoprotein-like nanoparticle - announced today that the company has completed its seed round investment bringing the total raised to $2 million in cash and in-kind support. MaRS Innovation joins the University Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in the company. The additional funds will be ...
Read more
Video: Canadian International Council interviews Rafi Hofstein about commercializing Canadian technology
Dr. Raphael Hofstein, president and CEO of MaRS Innovation, spoke to the Canadian International Council about the importance of protecting intellectual property as an important component in commercializing Canadian technologies.
Here's an excerpt:
Government could be extremely helpful if they created special funds dedicated to covering the costs of patent protection.
(more…)
Read more
